Trial Profile
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Refametinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 20 Apr 2020 Results published in the Targeted Oncology
- 02 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.